Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind, Parallel Group, Placebo-controlled Trial to Study the Efficacy and Safety of Two Oral Doses of Prurisol Administered Twice Daily for Twelve Weeks to Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT02949388 is registered in ClinicalTrials.gov with Innovation Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02949388
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02949388 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind, Parallel Group, Placebo-controlled Trial to Study the Efficacy and Safety of Two Oral Doses of Prurisol Administered Twice Daily for Twelve Weeks to Subjects With Moderate to Severe Chronic Plaque Psoriasis
Lead sponsor
Innovation Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2016
Completion date
December 31, 2017
Enrollment
199 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

chronic stable plaque psoriasis